Welcome to the Pfizer EU Policy Website.

A Complex System Delivering Breakthroughs that Change Patients’ Lives
Research and development (R&D) is the foundation for discovering innovative medicines and vaccines that change patients’ lives. Pfizer’s R&D program is designed to develop safe and effective breakthroughs for patients across the globe.

A diverse pool of highly skilled and technically trained people is a fundamental building block of the European Innovation ecosystem. People are the engine that fuels the innovation that changes people’s lives.

Trade has long been one of Europe’s strengths, enabling economic growth across the continent, building links with allies and partners across the world, and contributing to greater resilience in global downturns. 

Intellectual property protection is the lifeblood of innovation. Patents, trademarks, trade secrets, copyright, and other incentives such as regulatory data protection (RDP) enable the development of new technologies and support a robust, knowledge-based European economy.

The European regulatory system has helped extend and improve the lives of millions of European citizens and beyond through provision of safe and effective medicines. Since its formation in 1995 the European Medicines Agency (EMA) has recommended the authorisation of over 1,400 medicines. However, in order to keep pace with pharmaceutical breakthroughs as well as remain competitive and respond to global health challenges, it is vital for Europe’s regulatory system to continue to evolve.